Latest Breaking News On - Investigator initiated - Page 1 : comparemela.com

NeuroSense s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent 2024-01-30

NeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent .

United statesTel avivJeffrey rosenfeldDilek mirMilad fakurianonunsplashNews networkProfessor of neurology at loma linda universityBiogen incEuropean medicines agencyNeurosense therapeutics ltdSense therapeuticsPer protocol populationMerit cudkowiczMassachusetts general hospitalJulieanne dorn professorHarvard medical school

NeuroSense Therapeutics Ltd: NeuroSense s ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024

NeuroSense Therapeutics Ltd: NeuroSense s ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Tel avivUnited statesJeffrey rosenfeldMilad fakurianStefan klotterDilek mirIchida stem cell labNeurosense therapeutics ltdUniversity of southern californiaEuropean medicines agencyBiogen incProfessor of neurology at loma linda universitySense therapeuticsPer protocol populationMerit cudkowiczMassachusetts general hospital

Neurosense Therapeutics (NRSN) Reports Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

Neurosense Therapeutics (NRSN) Reports Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Neurosense therapeutics ltdEuropean medicines agencyNeurosense therapeuticsPer protocolRating scale revisedSlow vital capacityInvestigator initiatedScientific advice

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial -December 14, 2023 at 09:25 am EST

A statistically significant, 37.4% difference , slowing of disease progression in ALSFRS-R, in patients treated with PrimeC compared to placebo, in the pre-specified Per Protocol population.

United kingdomDrug administrationExchange commission onNeurosense therapeutics ltdExchange commissionEuropean medicines agencyPer protocolNeurosense therapeuticsRating scale revisedSlow vital capacityInvestigator initiatedScientific adviceAlon ben noonOrphan drug designationEuropean medicinesSense therapeutics

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

A statistically significant, 37.4% difference (P=0.03), slowing of disease progression in ALSFRS-R, in patients treated with PrimeC compared to placebo, in the.

United kingdomNeurosense therapeutics ltdDrug administrationEuropean medicines agencyPer protocolNeurosense therapeuticsRating scale revisedSlow vital capacityInvestigator initiatedScientific adviceAlon ben noonOrphan drug designationEuropean medicinesSense therapeutics